SLC5A2 and atrial fibrillation: Along the lines of glucose metabolism, sodium-glucose cotransporter-2 (SGLT2) inhibitor, another anti-diabetic drug, that could prevent glucose reabsorption in the kidney, was shown to low stroke risk in patients with diabetes and atrial fibrillation (Chang et al., 2023).